EyePoint (EYPT) Cash & Current Investments (2010 - 2026)
EyePoint (EYPT) reported Cash & Current Investments of $222.5 million for Q1 2026, down 30.06% on a YoY basis from $318.2 million in Q1 2025, and down 27.29% sequentially from $306.1 million in Q4 2025.
EyePoint (EYPT) Cash & Current Investments (2010 - 2026) Analysis & Trends
EyePoint (EYPT) has 17 years of Cash & Current Investments data on file, last reported at $222.5 million in Q1 2026.
- For the quarter ending Q1 2026, Cash & Current Investments fell 30.06% year-over-year to $222.5 million; the trailing twelve-month figure through Mar 2026 stood at $222.5 million (down 30.06% YoY), and the FY2025 full-year result was $306.1 million, down 17.48% from the prior year.
- Cash & Current Investments declined to $222.5 million in Q1 2026, from $306.1 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $370.9 million in Q4 2024 to a low of $122.5 million in Q1 2023.
- A 5-year average of $229.8 million and a median of $222.5 million in 2026 frame the typical range for Cash & Current Investments.
- Across the five-year window, Cash & Current Investments sank 35.81% in 2023 and surged 144.44% in 2024, its largest moves.
- Tracing EYPT's Cash & Current Investments over 5 years: stood at $144.6 million in 2022, then surged by 129.0% to $331.0 million in 2023, then increased by 12.04% to $370.9 million in 2024, then slipped by 17.48% to $306.1 million in 2025, then fell by 27.29% to $222.5 million in 2026.
- Business Quant data shows EYPT's Cash & Current Investments at $222.5 million in Q1 2026, $306.1 million in Q4 2025, and $204.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | EyePoint | 1.07 Mn | -221.48 Mn | 168,000.00 | 222.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 222.55 Mn |
| Dec 31, 2025 | 306.09 Mn |
| Sep 30, 2025 | 204.02 Mn |
| Jun 30, 2025 | 255.73 Mn |
| Mar 31, 2025 | 318.19 Mn |
| Dec 31, 2024 | 370.91 Mn |
| Sep 30, 2024 | 253.79 Mn |
| Jun 30, 2024 | 280.25 Mn |
| Mar 31, 2024 | 299.35 Mn |
| Dec 31, 2023 | 331.05 Mn |
| Sep 30, 2023 | 136.01 Mn |
| Jun 30, 2023 | 142.50 Mn |
| Mar 31, 2023 | 122.47 Mn |
| Dec 31, 2022 | 144.56 Mn |
| Sep 30, 2022 | 157.26 Mn |
| Jun 30, 2022 | 171.17 Mn |
| Mar 31, 2022 | 190.78 Mn |
| Dec 31, 2021 | 211.56 Mn |
| Sep 30, 2021 | 119.71 Mn |
| Jun 30, 2021 | 127.60 Mn |